![Blake Scott](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Dr. Blake Scott is a Vice President & Research Analyst at Aquilo Capital Management LLC.
Dr. Scott joined McKinsey & Co.’s New York office as a management consultant.
He served a range of pharmaceutical clients, including projects on regulatory, commercial, and R&D considerations.
He supported diligence on immuno-oncology portfolios, assets, biotechnology partnerships, and overall research strategies.
He helped develop strategies to improve clinical trial design and oversight for oncology trials, and supported the management in large mergers and acquisitions in the pharmaceutical space.
Dr. Scott completed his PhD in Cellular and Molecular Medicine at the Johns Hopkins School of Medicine,
Anciens postes connus de Blake Scott
| Sociétés | Poste | Fin |
|---|---|---|
Aquilo Capital Management LLC
 Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Analyst-Equity | 01/11/2022 |
Formation de Blake Scott
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
1
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Finance |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Choisissez Zonebourse 
